EAH Eco Animal Health Group Plc

TIDMEAH

RNS Number : 4879C

Eco Animal Health Group PLC

23 February 2022

23 February 2022

ECO Animal Health Group plc

("the Company" or the "Group")

(AIM: EAH)

ECO RECIEVES TWO NEW MARKETING AUTHORISATIONS FOR AIVLOSIN(R) IN CHINA

ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health Limited ("ECO") has received two marketing authorisations from the Ministry of Agriculture and Rural Affairs ("MOA") of the People's Republic of China for the use of Aivlosin(R) Water Soluble Granules ("WSG"). Aivlosin(R) is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in pigs and poultry.

The first approval allows ECO to market Aivlosin(R) WSG in China for the treatment of respiratory disease caused by Mycoplasma and other sensitive bacteria in chickens laying eggs for human consumption and breeding chickens. Aivlosin(R) is the first antimicrobial to be licensed by the Chinese MOA for laying birds with a zero day drug withdrawal period for eggs.

The second Aivlosin(R) WSG approval is for swine respiratory disease ("SRD") adding three important bacterial respiratory pathogens of swine, Haemophilus parasuis, Pasteurella multocida, and Streptococcus suis to the existing Mycoplasma hyopneumoniae registration. SRD occurs worldwide and causes major economic losses to the pig industry due to mortality, reduction in growth rates and decreased feed efficiency.

Marc Loomes, CEO, commented: "We are delighted to receive these important marketing authorisations for Aivlosin(R) WSG. China is the world's largest producer of table eggs and accounts for more than a third of the world's laying birds. Aivlosin(R) is the first antimicrobial registered for use in laying hens producing eggs for human consumption, with a zero day egg withdrawal period. This will enable ECO to target a new sector, the commercial egg producer, where Mycoplasmosis can cause significant economic losses. China is also the largest pork producing country in the world and broader product label claims in the key SRD segment will serve our business well as the market recovers in the future."

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR") as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

Contacts:

 
 
   ECO Animal Health Group plc 
   Marc Loomes (CEO) 
   Christopher Wilks (CFO)                     020 8447 8899 
 IFC Advisory 
  Graham Herring 
  Zach Cohen                                  020 3934 6630 
 Singer Capital Markets (Nominated Adviser 
  & Joint Broker) 
  Mark Taylor 
  George Tzimas                               020 7496 3000 
 Peel Hunt LLP (Joint Broker) 
  James Steel 
  Dr Christopher Golden                       020 7418 8900 
 Investec (Joint Broker) 
  Gary Clarence 
  Alex Penney 
  Carlo Spingardi                             020 7597 5970 
 Equity Developments 
  Hannah Crowe 
  Matt Evans                                  020 7065 2692 
 

About ECO Animal Health

ECO Animal Health Group plc ("ECO" or "the Group") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCTTMLTMTTTBFT

(END) Dow Jones Newswires

February 23, 2022 02:00 ET (07:00 GMT)

Eco Animal Health (LSE:EAH)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Eco Animal Health (LSE:EAH)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024